10x Genomics acquires CartaNA AB

10x Genomics acquired CartaNA AB for $41.8 million, a transaction completed in August 2020, structured as Acquisition of all outstanding shares; total $41.8M inclusive of $0.6M transaction costs and net of $1.5M cash acquired (funded with cash and stock).

CartaNA AB operates in In Situ Analysis, is based in Stockholm, Sweden. Acquisition of Stockholm-based CartaNA AB, a developer of In Situ RNA analysis technology that came out of Mats Nilsson's SciLifeLab at Stockholm University. The acquisition closed August 21, 2020 and was disclosed alongside the ReadCoor agreement on October 5, 2020.

Build comprehensive foundational IP, key technology advances and expertise in the emerging In Situ field to establish a third technology platform complementary to Chromium and Visium.

In Situ IP and talent combined with internal innovation to form the foundation of the Xenium platform; integrated into 10x's Swedish research center. In Situ Analysis / Xenium platform (Swedish research center, Stockholm)